Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Profound Medical ( (TSE:PRN) ) has shared an update.
Profound Medical Corp. has raised approximately $36 million through a registered direct offering of 5,142,870 common shares priced at $7.00 each, in a deal led by healthcare-focused investors and existing shareholders, with no warrant coverage. The company plans to deploy the net proceeds to expand sales and marketing, bolster working capital, fund research and development, pursue strategic transactions, and support general corporate purposes, and it also intends to complete an additional private placement for certain Canadian investors by December 30, 2025, subject to regulatory approvals, further strengthening its balance sheet and growth capacity.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapies for ablating diseased tissue. Its flagship product, TULSA-PRO, enables the TULSA Procedure, a robotically driven, transurethral ultrasound treatment designed to offer a precise, radiation-free, one-session option across the prostate disease spectrum, including various risk levels of prostate cancer and benign prostatic hyperplasia, while aiming to preserve urinary continence and sexual function.
Average Trading Volume: 20,928
Technical Sentiment Signal: Buy
Current Market Cap: C$315.8M
See more insights into PRN stock on TipRanks’ Stock Analysis page.